Trial Profile
Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary) ; Insulin aspart/insulin protamine aspart
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 20 Aug 2012 Actual end daet (1 May 2012) added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2011 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.